SHL Telemedicine (SHLT) Stock Price, News & Analysis

Company Overview

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel.

Key Stats

• Today's Range: $2.80 to $2.90
• 50-Day Range: $2.60 to $3.84
• 52-Week Range: $2.60 to $10.44
• Volume: 676 shs
• Average Volume: 3,452 shs
• Market Capitalization: $42.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

SHL Telemedicine Stock Analysis - MarketRank™

SHL Telemedicine scored higher than 42% of companies evaluated by MarketBeat, and ranked 687th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

SHL Telemedicine has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

SHL Telemedicine has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

SHL Telemedicine has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SHLT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SHL Telemedicine does not currently pay a dividend.

Dividend Growth

SHL Telemedicine does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for SHLT.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

SHL Telemedicine has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

MarketBeat Follows

1 people have added SHL Telemedicine to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SHL Telemedicine insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 20.11% of the stock of SHL Telemedicine is held by institutions.

SHLT Stock Analysis - Frequently Asked Questions

How have SHLT shares performed this year?

SHL Telemedicine's stock was trading at $7.98 at the beginning of 2024. Since then, SHLT stock has decreased by 63.7% and is now trading at $2.90.
View the best growth stocks for 2024 here.

How do I buy shares of SHL Telemedicine?

Shares of SHLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of SHL Telemedicine own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SHL Telemedicine investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU).

Company Calendar

• Today: 10/31/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Offices & clinics of medical doctors
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SHLT
• CUSIP: N/A
• CIK: 1166834
• Web: www.shl-telemedicine.com
• Phone: 972-3-561-2212
• Fax: N/A
• Employees: 583
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $11.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +279.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 2.17
• Quick Ratio: 1.98

Sales & Book Value

• Annual Sales: $57.08 million
• Price / Sales: 0.75
• Cash Flow: $0.05 per share
• Price / Cash Flow: 63.95
• Book Value: $5.21 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 14,680,000
• Free Float: N/A
• Market Cap: $42.57 million
• Optionable: Not Optionable
• Beta: -0.54